Economic and health impact of temporary HPV vaccination on older women and synergies with subsequent screening. (Q3136891): Difference between revisions
Jump to navigation
Jump to search
(Created claim: summary (P836): Background: In 2007, HPV vaccination was incorporated into the Spanish vaccination calendar for girls between the ages of 11-14. Efficient prevention will require that vaccinated cohorts need to be screened for cervical cancer (CCU) less frequently and delay the age of the first screening. Meanwhile, ~14 million women in Spain between 25-65 years have not been vaccinated and will need a thorough screening representing a significant budgetary and...) |
(Changed label, description and/or aliases in en: translated_label) |
||
| label / en | label / en | ||
Economic and health impact of temporary HPV vaccination on older women and synergies with subsequent screening. | |||
Revision as of 13:40, 12 October 2021
Project Q3136891 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Economic and health impact of temporary HPV vaccination on older women and synergies with subsequent screening. |
Project Q3136891 in Spain |
Statements
24,625.0 Euro
0 references
49,250.0 Euro
0 references
50.0 percent
0 references
1 January 2017
0 references
31 March 2020
0 references
INSTITUTO DE INVESTIGACION BIOMEDICA DE BELLVITGE
0 references
41°21'35.50"N, 2°5'59.24"E
0 references
08101
0 references
Antecedentes: En el 2007 se incorporó la vacunación del VPH al calendario vacunal español a niñas entre 11-14 años. Una prevención eficiente requerirá que las cohortes vacunadas deban cribarse para cáncer de cuello uterino (CCU) con menor frecuencia y retrasar la edad del primer cribado. Mientras tanto, ~14 millones de mujeres en España entre 25-65 años no han sido vacunadas y necesitarán un cribado exhaustivo representando una carga asistencial y presupuestaria importante. Estudios recientes muestran que la eficacia de las vacunas del VPH en mujeres de hasta 55 años es también muy alta (~85%). Cualquier estrategia poblacional debe evaluarse antes de su implementación y valorar su impacto sanitario y presupuestario. Objetivos: 1) Evaluar el coste-efectividad de la vacunación temporal de mujeres = 25 años y las sinergias con el cribado posterior 2) Proponer estrategias económicamente sostenibles que integren vacunación y cribado con protocolos específicos por grupos de edad 3) Evaluar el impacto económico de las estrategias propuestas en el presupuesto público de sanidad 4) Ofrecer consejo técnico a las sociedades científicas y autoridades sanitarias sobre los protocolos y su sostenibilidad. Metodología: Se construirá un modelo de microsimulación sobre la historia natural del CCU y el VPH calibrado a los datos de España. Las variables resultantes serán el riesgo de CCU, la esperanza de vida y los costes medios totales que permitirán evaluar la reducción en el riesgo de CCU y los QALYs. Para la comparación de estrategias, se realizará un análisis de coste-efectividad mediante razones incrementales de coste efectividad en € por QALY ganado. Los resultados de este proyecto permitirán orientar a los decisores sanitarios del SNS sobre las nuevas estrategias de prevención del CCU más eficientes. (Spanish)
0 references
Background: In 2007, HPV vaccination was incorporated into the Spanish vaccination calendar for girls between the ages of 11-14. Efficient prevention will require that vaccinated cohorts need to be screened for cervical cancer (CCU) less frequently and delay the age of the first screening. Meanwhile, ~14 million women in Spain between 25-65 years have not been vaccinated and will need a thorough screening representing a significant budgetary and care burden. Recent studies show that the efficacy of HPV vaccines in women up to 55 years of age is also very high (~85 %). Any population strategy must be evaluated before its implementation and its health and budgetary impact should be assessed. Objectives: 1) Evaluate the cost-effectiveness of temporary vaccination of women = 25 years and synergies with subsequent screening 2) Proposing economically sustainable strategies integrating vaccination and screening with age group specific protocols 3) Assessing the economic impact of proposed strategies in the public health budget 4) Offering technical advice to scientific societies and health authorities on protocols and their sustainability. Methodology: A microsimulation model will be built on the natural history of CCU and HPV calibrated to data from Spain. The resulting variables will be the CCU risk, life expectancy and total average costs to assess the risk reduction of CCU and QALYs. For the comparison of strategies, a cost-effectiveness analysis will be carried out using incremental cost-effectiveness reasons in EUR per QALY earned. The results of this project will provide guidance to health decision makers of the SNS on the new, more efficient CCU prevention strategies. (English)
12 October 2021
0 references
Hospitalet de Llobregat, L'
0 references
Identifiers
PI16_01254
0 references